Ascendis Pharma (ASND) Misses Q3 EPS by EUR0.04

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. SPY
8. XYZ
9. ANET
10. CVS

Go back to Ascendis Pharma (ASND) Misses Q3 EPS by EUR0.04

Ascendis Pharma A/S Reports Third Quarter 2016 Financial Results

November 30, 2016 4:01 PM EST

COPENHAGEN, Denmark, Nov. 30, 2016 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced financial results for the three months ended September 30, 2016.

"The third quarter was productive and successful as we outlined our Vision 20/20 strategic roadmap, initiated the TransCon Growth Hormone Phase 3 heiGHt Trial, and announced two additional pipeline programs, TransCon Parathyroid Hormone (PTH) and TransCon C-Type Natriuretic Peptide (CNP)," commented Jan Mikkelsen, President and Chief Executive Officer.  "We... More